Antibody drug conjugates (ADC) market size is projected to grow at a compound annual growth rate of 23.7% over the forecast period of 2022 to 2029. Data Bridge Market Research report on antibody drug conjugates (ADC) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.  In addition, the increase in product launches and approvals by market players along with increasing number of research and development activities are likely to create various new opportunities that will impact this antibody drug conjugates (ADC) market growth in the forecast period of 2022 to 2029. The low awareness regarding these biopharmaceuticals agents is estimated to challenge the market’s growth.



Get Your Sample Today:


Market Analysis and Insights Antibody drug conjugates market


Antibody drug conjugates are basically the biopharmaceuticals agents that are manufactured for targeted therapy of cancer treatment. They are covalently linked to the antibody or antibody fragment that directed towards the specific cell surface target expressed on the tumor cells. They are combined with monoclonal antibodies to target the cancer cells and act by specifically targeting to the tumor antigen surface, the complex internalized into the cells. 

The factors such as rising prevalence of cancer related disorders worldwide and emerging markets across the globe are expected to accelerate the market growth in the forecast period of 2022 to 2029. Furthermore, the increased research and clinical trials and growing cases of breast cancer in female will further carve the way for the growth of the market. However, the stringent FDA guidelines for the drug approval of new drug is projected to restraint the market growth rate. On the other hand, the adverse effect after the treatment in some cases also hampers the overall growth of the market.

This antibody drug conjugates (ADC) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the antibody drug conjugates (ADC) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.


Buy Now Access Full Report:-


Global Antibody drug conjugates market Scope and Market Size


Antibody drug conjugates (ADC) market is segmented on the basis of target, product, mechanism of action, technology, indication, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

·       On the basis of target, the market is segmented into antibody-protein toxin conjugates, antibody-chelated radionuclide conjugates, antibody-small-molecule drug conjugates and antibody-enzyme conjugates.

·       On the basis of product, the market is segmented into adcertis, kadcyla and others.

·       On the basis of mechanism of action, the market is segmented into cd30 antibodies and her2 antibodies.

·       On the basis of technology, the market is segmented into immunogen technology, seattle genetics technology, immunomedics technology and others.



Antibody drug conjugates market Country Level Analysis


The countries covered in the antibody drug conjugates (ADC) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the antibody drug conjugates (ADC) market due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals in this region. Asia-Pacific region, on the other hand is expected to expand at a significant growth rate because of the increased government awareness programs and number of generic drugs and rising cancer and bone marrow surgeries within the region.


Browse The Table of Contents And List of Figures:


Major TOC of the Antibody drug conjugates market Report

Chapter One:






Competitive Landscape and Antibody drug conjugates market Share Analysis


Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to antibody drug conjugates (ADC) market.

Some of the major players operating in the antibody drug conjugates (ADC) market report are  

·       Seagen Inc.,

·       Genentech Inc.,

·       Pfizer Inc.,

·       Novartis AG,

·       F. Hoffmann-LA Roche Ltd.,

·       Bristol -Myers Squibb,

·       Merck & Co., Inc.

·       Immunomedics Inc.,

·       Takeda Pharmaceutical Company Limited,

·       Onconova Therapeutics,

·       Helsinn Healthcare SA,

·       Abbott,

·       Boehringer Ingelheim International GmbH,

·       Johnson & Johnson Private Limited,


·       and AbbVie Inc., among others.



About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market



Data Bridge Market Research

Tel: +1-888-387-2818



Browse Related Reports@

Global Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market

Europe Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market

Asia-Pacific Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market

Middle East and Africa Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market